Sana director granted options on 90,000 shares

Sana Biotechnology, Inc. director Hans Edgar Bishop received a grant of stock options covering 90,000 shares of Common Stock at an exercise price of $2.96 per share.

Rhea-AI Filing Summary

Sana Biotechnology, Inc. director Hans Edgar Bishop received a grant of stock options covering 90,000 shares of Common Stock at an exercise price of $2.96 per share. Following this grant, he holds options on 90,000 shares directly.

The options vest and become exercisable for all 90,000 underlying shares on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual meeting of stockholders, provided he continues to serve the company through that date.

Insider Trade Summary

Grant/Award: 90,000 shares

Grant/Award 1 txn

Insider Bishop Hans Edgar

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	90,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 90,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

Key Figures

Option grant size: 90,000 shares Exercise price: $2.96 per share Total options after grant: 90,000 shares +2 more

5 metrics

Option grant size 90,000 shares Stock Option (Right to Buy) granted to director

Exercise price $2.96 per share Conversion or exercise price of options

Total options after grant 90,000 shares Total derivative shares following transaction

Expiration date June 3, 2036 Option expiration date

Vesting date trigger June 4, 2027 Earlier of this date or 2027 annual meeting, with continued service

Key Terms

Stock Option (Right to Buy), exercise price, vests and becomes exercisable, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "2.9600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests and becomes exercisable financial

"The option vests and becomes exercisable as to 100% of the underlying shares"

annual meeting of stockholders financial

"immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc."

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Sana Biotechnology (SANA) director Hans Edgar Bishop report in this Form 4?

He reported receiving a grant of stock options for 90,000 shares of Sana Biotechnology Common Stock at an exercise price of $2.96 per share. These are compensation-related awards, not open-market purchases or sales of existing shares.

What are the key terms of Hans Edgar Bishop’s new options at Sana Biotechnology (SANA)?

The options cover 90,000 shares of Common Stock with a $2.96 per-share exercise price and expire on June 3, 2036. They vest in full on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholders’ meeting, subject to continued service.

When do the newly granted Sana Biotechnology (SANA) options to Hans Edgar Bishop vest?

They vest and become exercisable for all 90,000 underlying shares on the earlier of June 4, 2027, or immediately prior to the 2027 annual meeting of stockholders, provided Bishop continues to provide service to Sana Biotechnology until that date.

Is Hans Edgar Bishop buying or selling Sana Biotechnology (SANA) shares in this Form 4?

This Form 4 does not show open-market buying or selling. It reports a compensation-related option grant coded “A” for 90,000 shares, giving Bishop the right to buy Sana Common Stock later at a fixed $2.96 exercise price if the options vest.

How many Sana Biotechnology (SANA) options does Hans Edgar Bishop hold after this transaction?

After the reported grant, Bishop holds stock options on 90,000 shares of Sana Biotechnology Common Stock directly. This total reflects the newly awarded options reported in the filing and represents his option position visible from this Form 4 entry.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bishop Hans Edgar

(Last) (First) (Middle)

C/O SANA BIOTECHNOLOGY, INC.

188 EAST BLAINE STREET, SUITE 350

(Street)

SEATTLE WASHINGTON 98102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.96	06/04/2026		A		90,000		(1)	06/03/2036	Common Stock	90,000	$0.00	90,000	D

Explanation of Responses:

1. The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

Remarks:

	/s/ Aaron M. Grossman, Attorney-in-Fact for Hans Edgar Bishop	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)